Literature DB >> 2968822

Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome.

Y Hayashi1, M Eguchi, K Sugita, S Nakazawa, T Sato, S Kojima, F Bessho, S Konishi, T Inaba, R Hanada.   

Abstract

Cytogenetic, immunologic, and electron microscopic studies were performed on the blast cells of 28 pediatric patients with Down's syndrome, 13 with acute leukemia (DS-AL) and 15 with transient myeloproliferative disorders (DS-TMD). Clonal chromosome abnormalities were found in the cells of all patients with DS-AL but not those with DS-TMD. The younger ages and higher hemoglobin concentrations, platelet counts, and WBC counts of DS-TMD patients provided a clinical contrast with the frankly leukemic cases. Myelodysplastic syndrome, characterized by a small percentage of leukemic blast cells, was observed in 11 of the 13 patients with DS-AL compared with none in the DS-TMD group. Electron microscopy disclosed a positive platelet peroxidase reaction in each of the 11 DS-TMD patients and in nine of the 13 DS-AL patients. Immunologic studies revealed antiplatelet-megakaryocyte antigens on the blast cells of the majority of patients in both study groups. Our findings suggest that the blast cells in cases of DS-AL and DS-TMD arise from cells of the megakaryocytic lineage or from a myeloid progenitor with the capacity for megakaryocytic differentiation. The high risk of the development of AL in patients with DS who are less than 3 years old may be related to increased megakaryocyte proliferation in this age group.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968822

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

2.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Authors:  Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Joanne M Hilden; April D Sorrell; Mukta Sharma; Thomas W Loew; Robert J Arceci; Dorothy Barnard; John Doyle; Gita Massey; John Perentesis; Yaddanapudi Ravindranath; Jeffrey Taub; Franklin O Smith
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

3.  Improved outcome of acute myeloid leukaemia in Down's syndrome.

Authors:  J L Craze; G Harrison; K Wheatley; I M Hann; J M Chessells
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

4.  Leukaemia and transient leukaemia in Down syndrome.

Authors:  L Iselius; P Jacobs; N Morton
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

5.  Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.

Authors:  Hirokazu Kanegane; Sayaka Watanabe; Keiko Nomura; Gang Xu; Etsuro Ito; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

6.  Childhood myelodysplastic syndromes: clinical features, cytogenetics and prognosis.

Authors:  R Nair; U A Athale; R S Iyer; C N Nair; S K Pai; P A Kurkure; P R Kadam; S H Advani
Journal:  Indian J Pediatr       Date:  1992 Jul-Aug       Impact factor: 1.967

7.  Congenital acute megakaryocytic leukemia.

Authors:  N B Mathur; Neha Joshi; T Singh; Meeta Singh
Journal:  Indian J Med Paediatr Oncol       Date:  2011-07

8.  A Case Report: Acute Myeloid Leukemia (FAB M7).

Authors:  R Masoumi-Dehshiri; As Hashemi; H Neamatzadeh; H Zare-Zardeini
Journal:  Iran J Ped Hematol Oncol       Date:  2014-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.